SEC Form 4 · accession 0001649989-26-000007
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence A Kenyon
Officer — Chief Financial Officer · Director
Period of report
Jul 21, 2026
Accepted (ET)
Jul 23, 2026 · 7:49 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.4304 | Jul 21, 2026 | A | 210,078 | A | Jul 21, 2027 | Jul 21, 2036 | Common Stock | 210,078 | 210,078 | D |
Explanation of responses
- F1The option was granted to Mr. Kenyon on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Kenyon's continuing service with the Issuer through such vesting date.